KalVista Pharmaceuticals, Inc.
KALV
$19.56
-$1.30-6.23%
NASDAQ
| 12/31/2025 | 09/30/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -31.31% | -38.26% | -32.69% | -14.38% | -2.04% |
| Gross Profit | 121.57% | 54.50% | 34.22% | 14.38% | 2.04% |
| SG&A Expenses | 98.78% | 110.77% | 123.81% | 106.14% | 147.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.39% | 28.85% | 29.77% | 32.20% | 44.76% |
| Operating Income | 3.51% | -19.92% | -28.86% | -32.20% | -44.76% |
| Income Before Tax | -1.41% | -32.25% | -37.10% | -39.66% | -55.53% |
| Income Tax Expenses | -185.70% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 3.19% | -37.28% | -41.01% | -42.34% | -59.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.19% | -37.28% | -41.01% | -42.34% | -59.45% |
| EBIT | 3.51% | -19.92% | -28.86% | -32.20% | -44.76% |
| EBITDA | 3.80% | -19.93% | -28.94% | -32.30% | -44.95% |
| EPS Basic | 14.64% | -10.46% | -9.43% | -6.59% | -16.63% |
| Normalized Basic EPS | 10.96% | -6.54% | -6.38% | -4.43% | -13.82% |
| EPS Diluted | 14.64% | -10.46% | -9.43% | -6.59% | -16.63% |
| Normalized Diluted EPS | 10.96% | -6.54% | -6.38% | -4.43% | -13.82% |
| Average Basic Shares Outstanding | 14.05% | 24.50% | 29.32% | 34.77% | 36.95% |
| Average Diluted Shares Outstanding | 14.05% | 24.50% | 29.32% | 34.77% | 36.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |